553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19

BACKGROUND: Background:: Immune modulation in patients with clinical features suggestive of a cytokine release syndrome (CRS) has become a pharmacologic target for potential treatment of COVID-19 and prevention of ARDS. Tocilizumab is an IL-6 receptor blocker FDA-approved for chimeric antigen recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Leonard, Michael, Asher, anthony, Kooken, Banks, Donahue, Erin, Symanowski, james, Roshdy, Danya, onsrud, jennifer, Umani, Saad, Copelan, edward, shahid, zainab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777929/
http://dx.doi.org/10.1093/ofid/ofaa439.747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777929/
http://dx.doi.org/10.1093/ofid/ofaa439.747

Ejemplares similares